Bladder cancer: Keytruda is prescribed to adults ... So don’t be afraid to ask questions or offer feedback on your treatment. For a list of Keytruda’s uses, see the “What is Keytruda used ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Sales momentum for the drug is still good, however, fuelled by a lengthening list of indications ... across early- and late-stage bladder cancer in various treatment combinations, including ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

Lower abdominal visceral fat area (VFA), older age, and prolonged surgery are independent risk factors for developing ...

Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

The long-term rates of 10 prostate cancer surgery vs radiation side effects are high, which carries implications for decision-making.

Patients with advanced bladder ... cancer. Prof. Tran said, "While pan-FGFR inhibitors are available and approved for use in metastatic urothelial cancer, the known side effects of these drugs ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...